Sitaxentan Sodium

西他生坦钠

Report date: 2023/03/21 10:04:36
NME

Base Information

Drug NameSitaxentan Sodium
Drug Alias NameSitaxsentan西他塞坦钠西他生坦sitaxentanumThelin +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsHeart Failure, DiastolicHeart DiseasesPulmonary Arterial Hypertension +[5] 
Global Approved IndicationsHypertension, Pulmonary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2006/08/10
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Encysive Pharmaceuticals IncPfizer Ltd +[6] 
Active IndicationsN/A
Inactive IndicationsHeart Failure, DiastolicHeart DiseasesPulmonary Arterial Hypertension +[5] 

Other Information

ATC CodeC02KX03
Related LinksWikipediaDrugBankKEGG